Justin Najimian, who has mild hemophilia A and a platelet disorder, is currently a freshman attending Rutgers University in New Brunswick, NJ.
The aim of the McGill researchers was to assess whether, under the proper clinical management, risk with this procedure was still greater in bleeding disorder patients.
The results showed that patients receiving on-demand therapy experienced a significantly greater number of bleeds than those patients in the prophylaxis group.
Spark currently has investigational gene therapy candidates in clinical trials for both hemophilia A and hemophilia B.
The webinar will cover recent clinical trial data, choosing appropriate therapies, and patient-centered approaches to care.
The long-acting product will be available in the US after 2020.
The program aims to improve the efficacy of patient infusion logs and reporting.
Catalyst reported data from their clinical study of marzeptacog alfa (MarzAA), a subcutaneous factor VIIa therapy that is being developed for treatment of people with hemophilia A or B with inhibitors.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car